Free Trial

Zynex (ZYXI) Stock Forecast & Price Target

Zynex logo
$2.88 -0.53 (-15.45%)
Closing price 03:59 PM Eastern
Extended Trading
$2.86 -0.02 (-0.76%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zynex - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
1

Based on 3 Wall Street analysts who have issued ratings for Zynex in the last 12 months, the stock has a consensus rating of "Hold." Out of the 3 analysts, 2 have given a hold rating, and 1 has given a buy rating for ZYXI.

Consensus Price Target

$10.25
255.53% Upside
According to the 3 analysts' twelve-month price targets for Zynex, the average price target is $10.25. The highest price target for ZYXI is $15.00, while the lowest price target for ZYXI is $5.50. The average price target represents a forecasted upside of 255.53% from the current price of $2.88.
Get the Latest News and Ratings for ZYXI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Zynex and its competitors.

Sign Up

ZYXI Analyst Ratings Over Time

TypeCurrent Forecast
3/13/24 to 3/13/25
1 Month Ago
2/12/24 to 2/11/25
3 Months Ago
12/14/23 to 12/13/24
1 Year Ago
3/14/23 to 3/13/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
2 Buy rating(s)
2 Buy rating(s)
3 Buy rating(s)
Hold
2 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.25$14.00$14.00$21.33
Forecasted Upside255.53% Upside87.17% Upside71.99% Upside68.11% Upside
Consensus Rating
Hold
Buy
Buy
Buy
Remove Ads

ZYXI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ZYXI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Zynex Stock vs. The Competition

TypeZynexMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.82
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside243.38% Upside23,973.95% Upside21.67% Upside
News Sentiment Rating
Neutral News

See Recent ZYXI News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/12/2025HC Wainwright
2 of 5 stars
Yi Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$17.00 ➝ $15.00+114.29%
3/12/2025Royal Bank of Canada
4 of 5 stars
Shagun Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Sector Perform$11.00 ➝ $5.50-21.43%
3/12/2025LADENBURG THALM/SH SH
3 of 5 stars
Jeffrey Cohen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 04:05 PM ET.


ZYXI Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Zynex is $10.25, with a high forecast of $15.00 and a low forecast of $5.50.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ZYXI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYXI, but not buy additional shares or sell existing shares.

According to analysts, Zynex's stock has a predicted upside of 255.53% based on their 12-month stock forecasts.

Over the previous 90 days, Zynex's stock had 2 downgrades by analysts.

Zynex has been rated by research analysts at HC Wainwright, LADENBURG THALM/SH SH, and Royal Bank of Canada in the past 90 days.

Analysts like Zynex less than other "medical" companies. The consensus rating for Zynex is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ZYXI compares to other companies.


This page (NASDAQ:ZYXI) was last updated on 3/13/2025 by MarketBeat.com Staff
From Our Partners